Aug 19 |
BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…
|
Aug 14 |
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript
|
Aug 14 |
BrainStorm Cell Therapeutics GAAP EPS of -$0.04 in-line
|
Aug 14 |
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
Aug 13 |
BrainStorm Cell Therapeutics Q2 2024 Earnings Preview
|
Jul 24 |
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
|
Jul 10 |
BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…
|
Jul 8 |
IPO Roundup: Actuate Therapeutics, Autozi Internet, and more
|
Jul 8 |
Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
|
Jul 1 |
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
|